Release Date: 30-Aug-2023
Epkinly became the first bispecific antibody to be approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in May 2023. Epkinly was developed jointly by AbbVie and Genmab and is currently being commercialized by the latter in the US, the only region where it has marketing approval. Since its approval in May 2023, Genmab has reported Epkinly sales of DKK 39 million, or US$ 5.85 million, for the first half of 2023. Epkinly is being reviewed by the EMA under the brand name Tepkinly, and its approval in the EU and other areas is likely to improve sales in the coming years.
Download Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023
Download US Bispecific Antibody Market and Clinical Pipeline Insight 2028